AI Earnings Predictions for Niagen Bioscience Inc. (NAGE)

EX-99.1

2 ex991pressrelease-q22026.htm

EX-99.1

Document

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July

Launched Niagen Plus telehealth platform

Net sales of $29.8 million, including $24.2 million from Tru Niagen

Generated $1.6 million of operating cash flow year-to-date

Net income of $1.0 million and adjusted EBITDA of $3.0 million

LOS ANGELES, CA - August 4, 2026 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

Second Quarter 2026 Financial and Business Highlights

•Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23% year-over-year.

•Gross margin of 64.8%, reflecting continued strength in business mix.

•Net income of $1.0 million, with basic and diluted earnings per share of $0.01.

•Adjusted EBITDA, a non-GAAP measure, was $3.0 million.

•Total cash provided by operations of $1.6 million during the six months ended June 30, 2026, ending with $66.7 million in cash and cash equivalents.

•Repurchased $2.8 million of common stock during the quarter.

•Launched Niagen Plus telehealth platform and made the at-home injection kit of Niagen Plus available to patients on niagenplus.com. The Company received LegitScript certification in June 2026, which allows for advertisement of Niagen Plus at-home injection kits.

•Introduced NB4168, a proprietary lead investigational therapeutic candidate for treatment of rare genetic diseases and aging related disorders, initially targeting Ataxia-Telangiectasia (A-T). NB4168 is an oral small molecule engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile.

•NB4168 received the Rare Pediatric Disease (RPD) designation for the treatment of A-T from the U.S. Food and Drug Administration, and Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency (EMA), supporting the Company's plans to advance the program globally.

•Engaged Evotec as its contract research organization for the preclinical and IND enabling studies for NB4168, anticipated to begin in Q3 2026.

•Renamed the ChromaDex External Research Program (CERP) to the Niagen Research Program, reflecting the Company's evolution and focus on advancing the understanding and applications of NAD+ through its flagship ingredient, Niagen®.

•Appointed Abhijit Kale, Ph.D., as Senior Director of Global External Research to lead the pharmaceutical program and oversee its expanding portfolio of external scientific collaborations. Dr. Kale previously served as a Scientific Review Officer at Hevolution Foundation and held scientific leadership roles at the Buck Institute for Research on Aging.

“During the quarter, Tru Niagen continued to demonstrate its category leadership, and at the same time, we laid the foundation strategically for what we expect will unlock tremendous value for years to come. The launch of our telehealth business and pharmaceutical program are long-term growth drivers that have evolved Niagen from a nutritional supplement business to a multi-asset anti-aging company,” said Rob Fried, Chief Executive Officer. “Our underlying consumer products business is the engine funding the rest of our value accretive initiatives and we are focused on investing across our multiple strategic growth opportunities, while maintaining cash flow of the business.”

2026 Outlook and Strategic Priorities:

For the full year 2026, the Company expects the e-commerce business to grow 10% to 15% year-over-year. We continue to expect the remainder of our consumer business to perform in line with our prior expectations. The ingredient business is expected to be lower than the prior year as some of our commercial partners continue to face a more competitive market, although we expect to add additional ingredient partners in the near term. We expect Niagen Plus growth and new skincare partnerships to become meaningful contributors beginning in 2027.

The Company believes 2026 is an important year of strategic investment and expects operating expenses to increase as it invests across commercial, research and administrative functions to support these strategic priorities, while continuing to focus on disciplined capital allocation and positive cash flow from operations.

Investor Conference Call

A live webcast will be held Tuesday, August 4, 2026 at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen Bioscience’s second-quarter financial results and provide a general business update.

To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investor Relations section of Niagen Bioscience’s website at https://investors.nia

EX-99.1

2 ex991pressrelease-q12026.htm

EX-99.1

Document

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Net sales increased to $31.5 million

Gross margin improved to 63.5%

Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million

LOS ANGELES, CA - May 6, 2026 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026.

First Quarter 2026 Financial Highlights

•Total net sales increased 3% to $31.5 million, including $22.4 million from Tru Niagen®. Excluding the recently sold Analytical Reference Standards and Services segment from both periods, net sales rose 5% to $31.1 million.

•Gross margin of 63.5%, reflecting continued strength in business mix.

•Net income of $6.3 million, including a $4.8 million gain on the divestiture of the Analytical Reference Standards and Services operating segment.

•Basic and diluted earnings per share were $0.08 and $0.07, respectively.

•Adjusted EBITDA, a non-GAAP measure, was $3.8 million.

•Working capital(1) increased by $5.4 million quarter-over-quarter.

•Used $1.2 million in operating cash flow during the quarter, driven by increased inventory levels and timing of receivables, ending with $66.5 million in cash and cash equivalents.

•Repurchased $2.4 million of common stock during the quarter.

•Updated full year 2026 outlook: Sales & marketing investment expected to increase; general & administrative expense outlook improved to up $3–$4 million (from $4–$5 million).

Recent Operational Highlights

•In May 2026, the Company launched a clinician-directed telehealth platform under Niagen Plus, enabling eligible U.S. patients to access prescription-based Niagen® at-home injection kits, expanding the Niagen Plus clinic channel beyond in-person settings and introducing a direct-to-patient access model.

•In April 2026, the Company announced the establishment of the first United States Pharmacopeia (USP) monograph for nicotinamide riboside chloride (NRCL), supported by the Company’s scientific analytical contributions, establishing a standardized quality benchmark for NR-based ingredients and reinforcing the Company’s leadership in NAD+ science and quality.

•In April 2026, the Company announced the addition of another 503B compounding partner, diversifying the Company’s 503B network and supply chain capabilities while expanding Niagen Plus to include new product offerings.

•In March 2026, the Company expanded the Niagen Plus clinical channel with its first cruise ship clinic partnership, enabling the availability of Niagen IV across more than 80 Medi-Spa clinics operated by OneSpaWorld aboard high-end cruise ships, further extending access through premium medical and wellness channels.

•In March 2026, the Company’s board of directors approved an increase of the Company’s share repurchase program to $20 million.

•In March 2026, the Company entered the skincare category through the launch of Niagen’s Nanocloud™, a topical product developed by the Niagen Skincare Innovation Lab, to evaluate market opportunity and generate consumer insights to guide future development.

•In February 2026, the Company completed the divestiture of the Analytical Reference Standards and Services operating segment to LGC Standards in an all-cash transaction, further streamlining operations and reinforcing its focus on core NAD+ science and commercial growth.

“We delivered $31.5 million of net sales and $6.3 million of net income for the first quarter,” said Niagen Bioscience CEO, Rob Fried. “Our results reflect continued execution across the business, including growth in our e-commerce channel and progress across key strategic initiatives. We are advancing our scientific leadership and expanding our commercial reach while remaining focused on disciplined investment and long-term value creation from our NAD+ platform.”

(1) Working capital is defined as current assets minus current liabilities in each period. Prior disclosures referenced operating working capital (accounts receivable, inventory, and accounts payable). The definition was updated in the current period to align with standard financial statement presentation and improve comparability.

Results of operations for the three months ended March 31, 2026 compared to the prior year quarter

Net Sales increased to $31.5 million. Excluding the impact of the divested segment in both periods, net sales increased approximately 5% year-over-year. The growth in net sales was driven by continued growth in Tru Niagen®, led by strong e-commerce performance and higher sales through different distribution channels, partially offset by variability in orders from A.S. Watson. Niagen® ingredient sales also contributed to the growth.

Gross Margin improving to 63.5%, reflecting favorable business mix and supply chain efficiencies.

Operating Expense increased 26%, or $3.8 million, to $18.4 million, reflecting planned investments to support

EX-99.1

2 exhibit991-pressreleasexq4.htm

EX-99.1

Document

EXHIBIT 99.1

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

Net sales increased 30% year-over-year to $129.4 million in 2025

Gross margin increased 250 bps year-over-year to 64.3% in 2025

Net income increased 103% year-over-year to $17.4 million in 2025

Adjusted EBITDA increased 139% year-over-year to $20.4 million in 2025

Cash and cash equivalents totaled $64.8 million at December 31, 2025 compared to $44.7 million at December 31, 2024

Full year 2026 net sales outlook reflects between 10-15% growth, excluding the recently sold reference standards segment.

LOS ANGELES, CA - March 4, 2026 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results.

Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter

•Total net sales increased 16% to $33.8 million, with Tru Niagen® sales of $27.5 million, up 21% from the prior year quarter.

•Gross margin increased 160 basis points to 64.1%.

•Net income of $4.1 million compared to $7.2 million in the prior year quarter. Q4 2024 benefited from a $3.5 million reversal of previously accrued royalties and license maintenance fees, and a $1.3 million recovery of credit losses related to the Elysium Health settlement, while the current-year quarter benefited from a $2.0 million gain related to the settlement of royalty obligations.

•Basic earnings per share was $0.05, and diluted earnings per share was $0.05, compared to $0.09 earnings per share in the prior year quarter for each.

•Adjusted EBITDA, a non-GAAP measure, was $4.1 million, an increase of $0.7 million from the prior year quarter.

Full Year 2025 Financial Highlights Compared to Prior Year

•Delivered on latest financial outlook across key metrics, demonstrating strong operational execution and focus on delivering shareholder value.

•Total net sales increased 30% to $129.4 million, with Tru Niagen® sales of $97.7 million and Niagen ingredient sales of $27.9 million, up 27% and 45%, respectively.

•Gross margin increased 250 basis points to 64.3%.

•Selling and marketing expense improved 220 basis points as a percentage of net sales to 27.4%, reflecting increased operating leverage.

•Net income of $17.4 million, an increase of $8.8 million from $8.6 million in the prior year. The prior year included a $3.5 million reversal of previously accrued royalties and license maintenance fees, while 2025 included a $2.0 million gain related to the settlement of royalty obligations. Both years included a $1.3 million recovery of credit losses related to the Elysium Health settlement.

•Basic earnings per share was $0.22, and diluted earnings per share was $0.20, improving from $0.11 earnings per share in the prior year for each.

•Adjusted EBITDA, a non-GAAP measure, was $20.4 million, increasing $11.9 million year-over-year.

•Generated positive operating cash flow of $13.5 million, ending the year with $64.8 million in cash and no outstanding borrowings.

Recent Operational Highlights

•In February, 2026, the Company sold substantially all of the assets of its analytical reference standards and services operating segment to a third party in an all-cash transaction for total consideration of approximately $6.0 million, less working capital adjustments of approximately $0.2 million. As of December 31, 2025, the assets of this segment were classified as held for sale and presented as such in the Company’s consolidated balance sheets.

•In January 2026, the Company announced a partnership with Truemed enabling qualified U.S. customers to use Health Savings Account (HSA) and Flexible Spending Account (FSA) funds to purchase Tru Niagen® on the Company’s direct-to-consumer website with a Truemed Letter of Medical Necessity (LMN). This update expands payment flexibility for eligible customers and reflects continued development of the Company’s consumer sales channels.

•In December 2025, the Company acquired the core nicotinamide riboside (NR) patent portfolio from Queen’s University Belfast, resulting in sole ownership of the foundational composition-of-matter intellectual property underlying NR and its salt forms. The acquisition enhances the Company’s control over key IP supporting existing and potential future applications, including pharmaceutical development, and increases strategic and financial flexibility for the development, licensing, and commercialization of its intellectual property portfolio.

•In November 2025, the Company launched Tru Niagen® Beauty, a dietary supplement formulated with Niagen® and other clinically studied ingredients designed to support skin, hair, and nail health. The product represents an expansion of the Company’s consumer portfolio into the beauty and nutricosmetics category and reflects the continued application of NAD+ science across additional cons

EX-99.1

2 ex991pressrelease-q32025.htm

EX-99.1

Document

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

Net sales increased 33% to $34.0 million

Gross margin increased 100 bps to 64.5%

Net income of $4.6 million, up $2.7 million from the prior year

Adjusted EBITDA increased by 120% to $6.4 million

Full year 2025 net sales outlook of 25% to 30% year-over-year growth

LOS ANGELES, CA - November 4, 2025 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the third quarter of 2025.

Third Quarter 2025 Financial Highlights Compared to Prior Year Period

•Total net sales increased 33% to $34.0 million, with Tru Niagen® sales of $26.0 million, up 44%.

•Gross margin increased 100 basis points to 64.5%.

•Sales and marketing expense as a percentage of net sales was 25.8%, an improvement of 170 basis points.

•Net income of $4.6 million or $0.06 earnings per share, up from $1.9 million or $0.02 earnings per share, in the prior year quarter.

•Adjusted EBITDA, a non-GAAP measure, increased 120% to $6.4 million.

•Total cash provided by operations of $12.8 million during the nine months ended September 30, 2025, ending the quarter with $64.3 million in cash.

•Full year 2025 outlook: Reaffirmed net sales growth expected between 25% to 30% (previously between 22% to 27%), driven by strong momentum in Tru Niagen® and Niagen® ingredients. Updated general and administrative and research and development expense outlook.

Recent Operational Highlights

•In September 2025, the Company launched AboutNAD®, a next-generation digital platform designed to serve as the leading online resource for scientific advancements in NAD+ research and healthy aging. The platform consolidates and curates peer-reviewed literature to make emerging science more accessible to consumers, clinicians, and researchers. This strategic initiative strengthens the Company’s position as the scientific leader in NAD+ biology, enhances brand visibility, and expands digital infrastructure to support future commercialization and partnership opportunities.

•In September 2025, the Company was successful in a National Advertising Division challenge against another entity making false claims about their NAD+ products. The National Advertising Division found no human clinical evidence that the competitor’s products elevate NAD+ levels in the body. The decision indicates the need for competent-and-reliable scientific evidence before advertisers make efficacy claims. This outcome reinforces the importance of rigorous scientific substantiation for claims in the NAD+ market and underscores the Company’s commitment to evidence-based positioning.

•In October 2025, the Company expanded the nationwide distribution network for pharmaceutical-grade Niagen Plus™ IV and injectable therapies to more than 1,000 clinics, including over 50 iCRYO locations. This expansion represents continued progress in scaling the Company’s clinical-grade NAD+ delivery network and broadening access for healthcare providers and wellness clinics offering NAD+-based boosting products for those seeking to improve cellular health and overall well-being.

“We delivered another strong performance with third quarter net sales of $34.0 million, up 33% year-over-year, and $4.6 million in net income,” said Niagen Bioscience CEO, Rob Fried. “Our results reflected the continued execution across the business, with sustained sales growth, margin expansion, and disciplined cost management. The progress across both scientific leadership and commercial reach reinforces our confidence in the long-term fundamentals of our leadership in the NAD+ category.”

Results of operations for the three months ended September 30, 2025 compared to the prior year quarter

Net Sales for Niagen Bioscience increased 33%, or $8.4 million, to $34.0 million. The growth in net sales was primarily driven by growth in Tru Niagen® sales, supported by strong e-commerce channel performance, as well as modest growth in Niagen® ingredient sales reflecting stronger demand for food-grade Niagen®.

Gross Margin improved 100 bps to 64.5% primarily due to changes in product mix, the use of lower-cost inventory purchases, and improvements in labor and overhead utilization rates with higher sales.

Operating Expense increased 21%, or $3.1 million, to $17.7 million reflecting investments for business growth and brand awareness.

•Sales and marketing expense increased $1.7 million and improved by 170 basis points as a percentage of net sales to 25.8% of net sales, reflecting improved sales efficiency and disciplined investment. The increase in expenses primarily reflected higher investments to support brand growth in our consumer products segment.

•General and administrative expense increased $0.8 million, or 13%, primarily driven by higher employee-related expenses, share-based compensation, and professional and consulting fees.

•Research and developme

EX-99.1

2 ex991pressrelease-q22025.htm

EX-99.1

Document

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Net sales increased 37% to $31.1 million

Gross margin increased 480 basis points to 65.0%

Net income of $3.6 million versus breakeven in prior year period

Adjusted EBITDA increased by 221% to $5.0 million

Raising full year 2025 revenue outlook to 22% to 27% year-over-year growth

LOS ANGELES, CA - August 6, 2025 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025.

Second Quarter 2025 Financial Highlights Compared to Prior Year Period

•Total net sales increased 37% to $31.1 million, with Tru Niagen® sales reaching $22.7 million, growing 22%.

•Niagen® ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade.

•Gross margin increased 480 basis points to 65.0%.

•Sales and marketing expense as a percentage of net sales was 26.4%, an improvement of 420 basis points.

•Net income of $3.6 million or $0.05 earnings per share, up from breakeven in prior year quarter.

•Adjusted EBITDA, a non-GAAP measure, increased 221% to $5.0 million.

•Total cash provided by operations of $9.1 million during the six months ended June 30, 2025, ending the quarter with $60.5 million in cash.

•Increased full year 2025 outlook: Net sales growth expected between 22%–27% (previously between 20%–25%), reflecting continued execution and leadership in the expanding NAD+ market.

Recent Operational Highlights

•On June 9, 2025, the Company announced the publication of the first peer-reviewed clinical study of Niagen® in individuals with Werner syndrome, a rare premature aging disorder in Aging Cell. The 52-week randomized trial showed Niagen® significantly increased NAD+ levels and improved clinical markers of cardiovascular and skin health, supporting further investigation in rare, age-related diseases.

•On July 8, 2025, the Company entered into a worldwide exclusive license agreement with Haukeland University Hospital in Bergen, Norway, securing proprietary rights to develop and commercialize its patented nicotinamide riboside (Niagen®) as a potential pharmaceutical therapy for Parkinson’s disease (PD). This agreement includes access to extensive clinical data, including from the Phase III NOPARK trial, and supports the Company’s broader efforts to advance regulated therapeutic applications for neurodegenerative conditions.

•During June 2025, patient dosing the Phase III NOPARK trial was completed, the largest and most comprehensive clinical study of NAD+ augmentation in persons with early PD to date. NOPARK is a randomized, double-blind, placebo-controlled phase III clinical trial featuring 400 individuals with early-stage PD across 12 sites in Norway. Randomized to receive either 500 mg of nicotinamide riboside (Niagen) twice daily or placebo for 52 weeks, participants had follow-up assessments at five time points in a one-year period. The primary endpoint is the MDS-UPDRS total score, a gold standard measure of PD progression. Data analysis is underway and the data from this phase 3 trial is expected to be published in 2026.

•On July 14, 2025, the Company announced the launch of Tru Niagen® as an exclusive in-room amenity, and introduced Niagen IV at The Spa by Equinox Hotel New York through NutriDrip, marking Niagen Bioscience’s entry into luxury hospitality. While featured at a single location, Equinox’s sole hotel property, the launch aligns with a premium, health-conscious demographic and serves as a potential model for broader hospitality partnerships.

•As of August 2025, Niagen Plus products, including Niagen IV and injectables, are available in over 800 leading wellness clinics in the U.S., up from more than 475 clinics in December 2024. This growth reflects accelerating adoption by clinics and rising demand for clinically administered NAD+ solutions. Niagen Plus products are compounded and distributed through U.S. FDA-registered 503B outsourcing facilities and offered exclusively by prescription through participating wellness clinics.

“We delivered an excellent second quarter, with $31.1 million in net sales, up 37% year-over-year, and $3.6 million in net income,” said Niagen Bioscience CEO Rob Fried. “As the pioneers of this blossoming NAD+ market, we continue to invest in the future while maintaining our focus on profitable growth."

Results of operations for the three months ended June 30, 2025 compared to the prior year quarter

Net Sales for Niagen Bioscience increased 37%, or $8.4 million, to $31.1 million. The growth in net sales was driven by combined growth in Tru Niagen® sales and Niagen® ingredient sales, including strong e-commerce channel performance, stronger demand for food-grade Niagen® and the ramp-up of pharmaceutical-grade Niagen® sales, which were not sold in the prior year quarter.

Gross Margin improved 480 basis points to 65.0% primarily due t

EX-99.1

2 ex991pressrelease-q12025.htm

EX-99.1

Document

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook.

LOS ANGELES, CA - May 7, 2025 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025.

First Quarter 2025 Financial and Recent Operational Highlights

•Total net sales were $30.5 million, with $21.5 million from Tru Niagen®, up 38%, and 24%, respectively, from the prior year quarter.

•Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% YoY.

•Delivered strong gross margin of 63.4%, up 270 basis points from the prior year quarter.

•Sales and marketing expense as a percentage of net sales was 26.6%, an improvement of 380 basis points, compared to 30.4% from the prior year quarter.

•Delivered net income of $5.1 million or $0.07 earnings per share, an improvement of $5.6 million and $0.08 per share from the prior year quarter.

•Adjusted EBITDA, a non-GAAP measure, was $4.9 million, a $4.2 million improvement from the prior year quarter.

•Total cash provided by operations of $7.9 million, ending the quarter with $55.6 million in cash.

•Increased full year 2025 outlook: Net sales growth expected between 20%–25% (previously approximately 18%), reflecting continued strength in the expanding NAD+ market. Adjusted general and administrative expenses now expected to increase $7.0–$8.0 million (previously $5.0–$6.0 million), primarily due to revised share-based compensation estimates. Full year 2025 outlook continues to project profitability.

•The Company announced its corporate name change to Niagen Bioscience, Inc. and commenced trading under the new Nasdaq ticker “NAGE,” effective March 19, 2025. This rebrand reflects the Company’s legacy and leadership in healthy aging through its flagship ingredient, Niagen®, reinforcing its renewed mission: “There’s a better way to age.”

•On March 20, 2025, the Company expanded its NAD+ precursor intellectual property portfolio with a newly granted patent which covers the composition of matter for nicotinamide riboside (NR) salt forms, including NR Malate and NR Tartrate, and other NR derivatives. This is part of a family of patents also covering methods of making NR and related derivatives, some of the most efficient NAD+ precursors, which Niagen Bioscience has obtained through an exclusive license from Queen’s University Belfast.

“We are proud to start the year with another record quarter, delivering $30.5 million in net sales, a 38% year-over-year growth fueled by both Tru Niagen® and strong Niagen® ingredient demand, a 63.4% gross margin, and $5.1 million in net income,” said Niagen Bioscience CEO Rob Fried. “With strong momentum heading into 2025, and with the launch of our new brand identity and expansion of our NAD+ precursor patent portfolio, we are reinforcing a powerful foundation for the future of healthy aging and are energized by the market’s growing trust in Niagen.”

Results of operations for the three months ended March 31, 2025 compared to the prior year quarter

Net Sales for Niagen Bioscience increased 38%, or $8.3 million, to $30.5 million. The growth in net sales was driven by combined growth in Tru Niagen sales and Niagen® ingredient sales, including a significant increase in food-grade Niagen® sales and the ramp-up of pharmaceutical-grade Niagen® sales, which were not sold in the prior year quarter.

Gross Margin improved 270 basis points to 63.4% primarily due to changes in product mix and business mix as well as improvements in labor and overhead utilization rates with higher sales.

Operating Expense increased 3%, or $0.4 million, to $14.6 million.

•Selling and marketing expense increased $1.4 million, and improved 380 basis points as a percentage of net sales to 26.6% of net sales, reflecting greater efficiencies from the increased investments which were primarily in advertising and marketing to support brand growth in our consumer products segment.

•General and administrative expense decreased 3%, or $0.2 million, driven by a $1.3 million recovery of credit losses related to a legal settlement, largely offset by increases in professional, consulting service and employee related expenses.

•Research and development expenses decreased $0.8 million, normalizing to historical levels compared to the prior year quarter, when spending was elevated to support the successful launch of the Niagen Plus product line, including work on pharmaceutical-grade Niagen®.

Net Income was $5.1 million, or $0.07 per share, compared to a net loss of $0.5 million or $(0.01) per share for the first quarter of 2024.

Adjusted EBITDA, a non-GAAP measure, was $4.9 million, up from $

EX-99.1

2 exhibit991-pressreleasexq4.htm

EX-99.1

Document

EXHIBIT 99.1

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net sales of $29.1 million, up 37% from the prior year, gross margin of 62.5%, and net income of $7.2 million.

LOS ANGELES, CA - March 4, 2025 - ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results.

Fourth Quarter 2024

•Total net sales of $29.1 million, with $22.7 million from Tru Niagen®, up 37% and 29%, respectively, from the prior year quarter.

•Posted strong gross margin of 62.5%, up 150 basis points from 61.0% in the prior year quarter.

•General and administrative expense decreased $4.4 million, which includes a $3.5 million reversal of previously accrued royalties and license maintenance fees and a $1.3 million recovery of credit losses related to the legal settlement with Elysium Health, LLC.

•Delivered record net income of $7.2 million, a $7.1 million improvement from $0.1 million in the prior year quarter.

•Basic and diluted earnings per share was $0.09, a significant improvement from approximately break-even earnings per share in the prior year quarter for each.

•Adjusted EBITDA, a non-GAAP measure, was $3.4 million, a $2.1 million improvement from the prior year quarter.

Full Year 2024 and Highlights

•Delivered on latest financial outlook, exceeding targets across all key performance metrics, reinforcing our strong execution and commitment to driving shareholder value by focusing on both top and bottom-line growth.

•Total net sales of $99.6 million, up 19%, with $76.8 million from Tru Niagen® and $19.2 million from Niagen ingredients, up 10% and 82%, respectively, year-over-year.

•Gross margin of 61.8%, an improvement of 100 basis points from 60.8% in the prior year.

•Selling and marketing expense as a percentage of net sales improved 200 basis points year-over-year.

•General and administrative expense decreased $6.6 million year-over-year, which includes a $3.5 million reversal of previously accrued royalties and license maintenance fees and a $1.3 million recovery of credit losses related to the legal settlement with Elysium Health, LLC.

•Achieved net income of $8.6 million, an improvement of $13.5 million, from a net loss of $4.9 million in the prior year.

•Basic and diluted earnings per share was $0.11, significantly improving from $0.07 loss per share in the prior year for each.

•Adjusted EBITDA, a non-GAAP measure, was $8.5 million, a $6.6 million improvement year-over-year.

•Positive operating cash flows of $12.1 million, ending the year with $44.7 million in cash and no debt.

•In 2024, ChromaDex launched Niagen Plus, a product line featuring pharmaceutical-grade Niagen®. These Niagen Plus products, including Niagen IV and injectables, are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively by prescription at participating wellness clinics. As of today, Niagen Plus products are available at over 475 leading wellness clinics in the U.S.

•In 2024, ChromaDex achieved key regulatory milestones, receiving Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for NR. The Company is actively engaged with the FDA to address regulatory considerations and advance its Investigational New Drug (IND) application for the treatment of Ataxia Telangiectasia (AT), a rare and progressive childhood disorder impacting neurological and immune function.

“ChromaDex proudly delivered a record breaking $29.1 million in net sales for the fourth quarter of 2024, up 37% from the prior year quarter, with $7.2 million in net income. This contributed to full year net sales of $99.6 million, a 19% increase year-over-year, along with $8.6 million in net income and $12.1 million in operating cash flow,” said Rob Fried, ChromaDex Chief Executive Officer. “With $44.7 million in cash and no debt, we believe we are in a strong position to navigate challenges, seize opportunities, and drive continued success in 2025 and beyond.”

Results of operations for the three months ended December 31, 2024 compared to the prior year quarter

Net Sales for ChromaDex increased 37%, or $7.9 million, to $29.1 million. Net sales growth was primarily driven by a $5.0 million increase in Tru Niagen® sales (primarily from e-commerce) and $2.9 million higher ingredient sales (primarily from food-grade Niagen).

Gross Margin improved 150 basis points to 62.5% primarily due to changes in product and business mix and improvements in labor and overhead utilization rates with higher sales.

Operating Expense decreased 15%, or $2.0 million, to $11.1 million.

•General and administrative (G&A) expense decreased b

EX-99.1

2 ex991pressrelease-q32024.htm

EX-99.1

Document

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and Adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024.

LOS ANGELES, CA - October 31, 2024 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024.

Third Quarter 2024 Financial and Recent Operational Highlights

•Total net sales were $25.6 million, with $18.1 million from Tru Niagen®, up 31%, and 4%, respectively, from the prior year quarter.

•Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $6.7 million, up 368% YoY.

•Delivered strong gross margin of 63.5%, up 210 basis points from the prior year quarter.

•Sales and marketing expense as a percentage of net sales was 27.5%, an improvement of 350 basis points, compared to 31.0% from the prior year quarter.

•Achieved net income of $1.9 million or $0.02 earnings per share, an improvement of $2.8 million and $0.03 per share from the prior year quarter.

•Reached record Adjusted EBITDA, a non-GAAP measure, of $2.9 million, up $2.4 million from the prior year quarter.

•In September 2024, ChromaDex expanded the availability of Niagen+, a product line containing pharmaceutical-grade Niagen®, to an additional 14 leading wellness clinics. These Niagen+ products, including Niagen® IV and Niagen® Injections, are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively by prescription at participating wellness clinics. As of October 31, 2024, ChromaDex has expanded Niagen+ availability to over 100 wellness clinics, with further significant expansion expected in the coming weeks.

•In September 2024, ChromaDex marked its 25th anniversary. Over the past 25 years, ChromaDex has built a reputation as the gold standard for scientific rigor and quality. With over 275 research agreements worldwide, more than 175 peer-reviewed publications, and over 30 human clinical studies on Niagen®, the ChromaDex External Research Program (CERP™) has played a pivotal role in advancing the scientific understanding of NAD+ and its role in age-related health conditions.

•ChromaDex has initiated discussions with the FDA and is working to schedule meetings as part of the Company’s efforts to pursue an Investigational New Drug (IND) application for the use of nicotinamide riboside (NR) in the treatment of Ataxia Telangiectasia (AT). AT is a rare, progressive disease that typically presents in early childhood and affects the function of the nervous system, the immune system, and several other body systems.

“We are proud to report our best quarter to date, achieving $25.6 million in revenue, an impressive 31% increase year-over-year, supported by a strong gross margin of 63.5%, record-setting net income of $1.9 million, and healthy cash flows that have grown our operating cash to $32.4 million,” said ChromaDex CEO Rob Fried. “These results reflect our growing financial strength and set the stage for even greater success. This quarter also marks the first sales of our Niagen+ products, and we look forward to further extending their availability to more wellness clinics as we continue to deliver innovative health solutions to our customers.”

Results of operations for the three months ended September 30, 2024 compared to the prior year quarter

Net Sales for ChromaDex increased 31%, or $6.1 million, to $25.6 million. The growth in net sales was primarily driven by increased Niagen® ingredient sales, including a significant increase in food-grade Niagen® sales and the introduction of pharmaceutical-grade Niagen, and more modest gains in Tru Niagen sales.

Gross Margin improved 210 basis points to 63.5% primarily due to changes in product mix and business mix, the recognition of deferred revenue, and improvements in labor and overhead utilization rates with higher sales.

Operating Expense increased 12%, or $1.5 million, to $14.6 million.

•Selling and marketing (S&M) expense increased $1.0 million and improved 350 basis points as a percentage of net sales to 27.5% of net sales, reflecting greater efficiencies from the increased investments.

•General and administrative expense increased 8%, or $0.5 million, driven by higher legal expense of $0.5 million to support the Niagen+ launch and litigation matters.

Net Income was $1.9 million, or $0.02 per share, compared to a net loss of $1.0 million or $(0.01) per share for the third quarter of 2023.

Adjusted EBITDA, a non-GAAP measure, was $2.9 million, up from $0.5 million for the third quarter of 2023. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of non-GAAP Adjusted EBITDA to net loss, the most directly comparable GAAP measure.

Cash Flows from Operating Activities had a net cash inflow of $3

EX-99.1

2 ex991pressrelease-q22024.htm

EX-99.1

Document

ChromaDex Corporation Reports Second Quarter 2024 Financial Results

Total net sales of $22.7 million, up 12% year-over-year, gross margin of 60.2%, lower operating expenses, resulting in approximately breakeven net loss and positive Adjusted EBITDA of $1.6 million for the three months ended June 30, 2024.

LOS ANGELES, CA - August 7, 2024 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2024.

Second Quarter 2024 Financial and Recent Operational Highlights

•Total net sales were $22.7 million, with $18.6 million from Tru Niagen®, up 12%, and 10%, respectively, from the prior year quarter.

•Solid gross margin of 60.2% and a $0.7 million reduction in total operating expenses from the prior year quarter.

•Net loss and loss per share were approximately breakeven, a $2.2 million and $0.03 per share improvement from the prior year quarter.

•Adjusted EBITDA, a non-GAAP measure, improved to $1.6 million from $0.2 million in the prior year quarter.

•In June 2024, ChromaDex announced U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for nicotinamide riboside chloride, ChromaDex’s product candidate for the treatment of Ataxia Telangiectasia (AT). AT is a rare, progressive disease that typically presents in early childhood and affects the function of the nervous system, the immune system, and several other body systems. Plans are underway to file an Investigational New Drug application with the U.S. FDA in anticipation of conducting human clinical trials. If the application is approved, ChromaDex will pursue grant funding or other non-dilutive financing for the human clinical trials.

•In June 2024, ChromaDex unveiled Niagen+, a product line featuring pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride or NRC). U.S. FDA-registered 503B outsourcing facilities will compound and distribute pharmaceutical-grade Niagen®, which will be available in intravenous (IV) and injectable forms exclusively at clinics with prescription. Beginning this month, Niagen IV and injections will debut at select IV clinics. Clinical study results(1) support Niagen IV offering a 75% shorter infusion time, a higher and faster rise in NAD+ blood levels three hours post-infusion, based on dried blood spot analysis, and is well-tolerated as compared to the common alternative, NAD+ IV.

•In July 2024, ChromaDex launched Niagen+ NAD+ Test Kits, available exclusively to healthcare practitioners. The Niagen+ NAD+ Test Kits provide a reliable method for measuring patient blood NAD+ levels, enabling practitioners to create more personalized and effective protocols using ChromaDex’s NAD+-boosting products, Tru Niagen® and Niagen+.

“We delivered solid financial results in the second quarter, with $22.7 million in revenue and lower operating expenses resulting in virtually breakeven net loss and operating cash flows, as well as positive Adjusted EBITDA of $1.6 million,” said ChromaDex Chief Executive Officer, Rob Fried. “Moreover, we are thrilled to finally unveil our new product line, Niagen+, for healthcare practitioners and clinics. This launch marks a significant milestone for ChromaDex, as we believe we are the first company to offer NR in both oral and intravenous forms, reinforcing our position as the global authority in the NAD+ market.”

(1) Source: MedRxiv Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen®+ IV and NAD+ IV in healthy adults

Results of operations for the three months ended June 30, 2024 compared to the prior year quarter

ChromaDex recorded net sales of $22.7 million, an increase of 12% or $2.4 million from the prior year quarter. The growth in total net sales was primarily due to higher Tru Niagen® and Niagen® ingredient sales.

Gross margin percentage declined 60 basis points to 60.2% primarily driven by changes in business mix.

Operating expense decreased 5%, or $0.7 million, to $13.9 million driven by lower general and administrative expense, partially offset by increased investments in sales and marketing expense.

Net loss and loss per share were approximately breakeven, both up compared to a net loss of $2.2 million, or $0.03 loss per share, for the second quarter of 2023. Adjusted EBITDA, a non-GAAP measure, improved to $1.6 million from $0.2 million in the second quarter of 2023. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of non-GAAP Adjusted EBITDA to net loss, the most directly comparable GAAP measure.

Net cash inflow from operating activities was approximately breakeven for the six months ended June 30, 2024 compared to a net cash inflow of $6.1 million in the prior year. The approximately $6.0 million reduction in cash provided by operating activities was largely driven by a relatively greater increase in trade receivables of $4.2 million and a greater reduction in accounts payable of $2.5 million.

2024 Full Year

EX-99.1

2 ex991-8kpressreleasexq12024.htm

EX-99.1

Document

ChromaDex Corporation Reports First Quarter 2024 Financial Results

Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%.

LOS ANGELES, CA - May 8, 2024 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2024.

First Quarter 2024 Financial and Recent Operational Highlights

•Total net sales were $22.2 million, with $17.4 million from Tru Niagen®.

•Solid gross margin of 60.7%, an increase of 80 basis points, compared to 59.9% from the prior year quarter.

•Sales and marketing expense as a percentage of net sales was 30.4%, an improvement of 450 basis points, compared to 34.9% from the prior year quarter.

•Total operating expenses decreased $1.3 million while increasing investments in research and development initiatives.

•Net loss was $0.5 million or $(0.01) per share, a $1.4 million improvement, or $0.02 per share, from the prior year quarter.

•Adjusted EBITDA, a non-GAAP measure, improved to a positive $0.7 million from a negative $0.1 million in the prior year quarter.

•In March 2024, the Tru Niagen® product portfolio(1) attained third-party verification through the Alkemist Assured™ testing transparency program conducted by Alkemist Labs, a distinguished third-party testing laboratory known for its rigorous analysis of herbal and dietary supplements. This verification reinforces ChromaDex's commitment to excellence by ensuring high-quality, safe ingredients and transparency.

•In April 2024, ChromaDex expanded distribution of Tru Niagen®, announcing partnerships with The Vitamin Shoppe and Sprouts Farmers Market, both targeting health-conscious consumers. Tru Niagen® is now available in 700 The Vitamin Shoppe and Super Supplements specialty retail locations and online, as well as in 400 Sprouts Farmers Market locations, marking the inaugural launch with a major U.S. grocery chain.

“During the first quarter of 2024, we delivered $22.2 million in revenue and, as anticipated, we increased investments in R&D to support our future launches, while continuing to demonstrate financial discipline across the business. We reduced total operating expenses, and delivered positive Adjusted EBITDA of $0.7 million, along with positive operating cash flows, ending with $27.6 million in cash and no debt,” said ChromaDex Chief Executive Officer, Rob Fried. “We are excited about the opportunities ahead as we intensify our efforts for new launches and continue to drive growth in our Tru Niagen business through strategic partnerships. I am proud of the progress made to date and look forward to another exciting year."

(1) Excluding Tru Niagen Pro 1,000 mg, which is NSF Certified for Sport®.

Results of operations for the three months ended March 31, 2024 compared to the prior year quarter

ChromaDex recorded net sales of $22.2 million, a decrease of 2% or $0.4 million from the prior year quarter. This decline in total net sales was primarily due to reduced Tru Niagen® sales, where growth in e-commerce sales was offset by decreased sales through distributor partners, primarily due to timing of sales.

Gross margin percentage improved 80 basis points to 60.7%. The slight improvement in gross margin percentage is primarily driven by changes in business mix.

Operating expense decreased 8%, or $1.3 million, to $14.2 million due to reductions in general and administrative expense as well as sales and marketing expense, partially offset by increased investments in research and development expense to support future launches.

Net loss was $0.5 million, or $0.01 loss per share, compared to a net loss of $1.9 million, or $0.03 loss per share, for the first quarter of 2023. Adjusted EBITDA, a non-GAAP measure, improved to a positive $0.7 million from a negative $0.1 million in the first quarter of 2023. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of non-GAAP Adjusted EBITDA to net loss, the most directly comparable GAAP measure.

Net cash inflow from operating activities was $0.3 million for the three months ended March 31, 2024 compared to a net cash inflow of $2.8 million in the prior year. The $2.5 million reduction in cash provided by operating activities was primarily driven by relatively greater reductions in accounts payable of $1.6 million and lower reductions in inventory and prepaid expenses and other assets of $0.7 million and $0.5 million, respectively.

2024 Full Year Outlook

Looking forward, for the full year, the Company expects the trajectory of full year revenue growth to continue, projecting a higher rate of revenue growth than the prior year growth of 16%. This outlook assumes continued revenue growth through our e-commerce business as well as established partnerships, and assumes upside from

EX-99.1

2 exhibit991-pressreleasexq4.htm

EX-99.1

Document

EXHIBIT 99.1

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows.

LOS ANGELES, CA - March 6, 2024 - ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results.

Fourth Quarter 2023 and Recent Highlights

•Total net sales of $21.2 million, with $17.6 million from Tru Niagen®, up 1% and 9%, respectively, from the prior year quarter.

•Delivered strong gross margin of 61.0%, an increase of 380 basis points, compared to 57.2% from the prior year quarter.

•Achieved net income of $0.1 million, a $1.5 million improvement from a net loss of $1.4 million in the prior year quarter.

•Adjusted EBITDA, a non-GAAP measure, was a positive $1.2 million, a $0.9 million improvement from the prior year quarter.

•Maintained positive operating cash flows for a fourth consecutive quarter, ending with $27.3 million in cash and no debt.

•In October 2023, launched clinical strength Tru Niagen® Pro 1,000 mg, proven to elevate NAD+ levels by 150% in three weeks.

•In November 2023, phase II clinical study published in the peer-reviewed journal, Movement Disorders, found that supplementation with Niagen® increased whole blood NAD+ levels up to fourfold, improved coordination and eye movement while maintaining biomarkers of stable liver and kidney function in Ataxia Telangiectasia (AT) patients.

•In November 2023, clinical trial published in the peer-reviewed journal, Nature Communications, found that high-dosages of Niagen® induces a potent NAD+ response and is associated with mild improvement in Parkinson's Disease.

Full Year 2023 Highlights

•Delivered on latest financial outlook to investors across all metrics, and exceeded targets for gross margin and general and administrative expense.

•Total net sales of $83.6 million, with $69.5 million from Tru Niagen®, each increasing 16% year-over-year.

•Gross margin of 60.8%, an improvement of 140 basis points from 59.4% in the prior year.

•Selling and marketing expense as a percentage of net sales improved 770 basis points year-over-year.

•General and administrative expense decreased $3.3 million year-over-year.

•Net loss of $4.9 million or $0.07 loss per share, an $11.6 million improvement, or $0.17 per share, year-over-year.

•Adjusted EBITDA, a non-GAAP measure, was a positive $1.9 million, a $11.9 million improvement year-over-year.

•In August 2023, expanded ChromaDex’s worldwide reach launching Tru Niagen® on iHerb, a global destination for supplements.

•In October 2023, Zesty Paws, a prominent name in pet supplements, partnered with ChromaDex to launch a Healthy Aging NAD+ Precursor supplement for pets, featuring Niagen®. This partnership marks the entry into the longevity category for pets and extends the power of Niagen® to animal companions.

•ChromaDex External Research Program (CERP™) celebrated its 10th anniversary, signing more than 275 global research agreements with over 235 independent, expert investigators to uncover the full potential of NAD+ with Niagen®. This research has shown that the health benefits of Niagen® translate from preclinical models to human clinical studies for brain, heart and muscle health with remarkable consistency. Looking to the next 10 years, there is great anticipation for emerging benefits in sensory, infant, maternal and reproductive health to be translated from preclinical to human studies.

“ChromaDex had its strongest year yet, achieving $83.6 million in revenue, up 16% year-over-year, with positive adjusted EBITDA of $1.9 million, and consistent positive operating cash flows each quarter. Additionally, the fourth quarter marked an important milestone with the company achieving positive net income,” said Rob Fried, ChromaDex Chief Executive Officer. “Ending the year with $27.3 million in cash and no debt underscores our financial strength. This solid foundation, paired with continued investments in our future, fuels our optimism as we set the stage for accelerated growth in 2024 and beyond. We're confident in our trajectory and excited about the new market opportunities ahead.”

Results of operations for the three months ended December 31, 2023 compared to the prior year quarter

ChromaDex reported net sales of $21.2 million, an increase of $0.2 million, or 1%. The increase was driven by a $1.5 million increase in Tru Niagen® sales, largely offset by a decline of $1.2 million in Niagen® ingredient sales since the prior year period included a $2.0 million upfront minimum purchase from Nestle Health Science.

Gross margin percentage improved 380 basis points to 61.0%. The increase in gross margin percentage is largely

EX-99.1

2 ex991-8kpressreleasexq32023.htm

EX-99.1

Document

ChromaDex Corporation Reports Third Quarter 2023 Financial Results

Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 million and positive operating cash flows for the three months ended September 30, 2023.

LOS ANGELES, CA - November 8, 2023 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2023.

Third Quarter 2023 and Recent Highlights

•Total net sales were $19.5 million, with $17.4 million from Tru Niagen®, up 14% and 19% from the prior year quarter, respectively.

•Strong gross margin of 61.4%, an increase of 160 basis points, compared to 59.8% from the prior year quarter.

•Sales and marketing expense as a percentage of net sales was 31.0%, an improvement of 340 basis points, compared to 34.4% from the prior year quarter.

•Net loss was $1.0 million or $(0.01) per share, remaining stable compared to the prior year quarter, a notable achievement as the prior year's results included the one-time Employee Retention Tax Credit recognition of $2.1 million ($0.03 per share).

•Adjusted EBITDA, a non-GAAP measure, was a positive $0.5 million, a $1.7 million improvement from the prior year quarter.

•In August 2023, launched Tru Niagen® on iHerb, a global destination for supplements, expanding ChromaDex’s worldwide reach.

•Clinical study published in August 2023 in the peer-reviewed journal Cell Reports found that supplementation of NR effectively reduced inflammation in both healthy subjects and immune cells derived from psoriasis patients.

•In October 2023, launched Tru Niagen® 1,000 mg, the most researched dosage in clinical studies, empowering customers to elevate their NAD levels by up to 150% after three weeks.

•In October 2023, Zesty Paws, a prominent name in pet supplements, partnered with ChromaDex to launch a Healthy Aging NAD+ Precursor supplement for pets, featuring Niagen®. This partnership marks the entry into the longevity category for pets and extends the power of Niagen® to animal companions.

“We had a solid quarter, delivering 14% year-over-year revenue growth, a net loss of only $1.0 million, positive Adjusted EBITDA of $0.5 million, and positive operating cash flows for the third consecutive quarter, ending with $26.8 million in cash and no debt,” said ChromaDex Chief Executive Officer, Rob Fried. “These results serve as a testament to our commitment to financial discipline and operational efficiency. ChromaDex is in its strongest financial position to date, and we expect to unlock commercial opportunities driven by new innovation in 2024 and beyond.”

Results of operations for the three months ended September 30, 2023 compared to the prior year quarter

ChromaDex reported a net sales increase of 14%, or $2.4 million, to $19.5 million. The increase in total net sales was driven by growth in Tru Niagen® sales, partially offset by lower Niagen® ingredient sales.

Gross margin percentage improved 160 basis points to 61.4%. The improvement in gross margin percentage is primarily driven by supply chain management optimization efforts, including improvements in yield loss, and benefits from economies of scale, partly offset by changes in business mix.

Operating expense decreased 1%, or $0.2 million, to $13.1 million due to a $0.3 million reduction in general and administrative expense, partially offset by a slight increase in sales and marketing expense.

Net loss was $1.0 million, or $0.01 loss per share, consistent with the net loss of $1.0 million or $0.01 loss per share for the third quarter of 2022. Notably, the third quarter of 2022 included a one-time recognition of the Employee Retention Tax Credit recognition of $2.1 million, or $0.03 per share, further underlining the improvements in performance this quarter compared to the prior year quarter. Adjusted EBITDA, a non-GAAP measure, was a positive $0.5 million, a $1.7 million improvement from the third quarter of 2022. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of non-GAAP Adjusted EBITDA to net loss, the most directly comparable GAAP measure.

Net cash inflow from operating activities was $6.5 million for the nine months ended September 30, 2023, showing a significant improvement compared to a net cash outflow of $14.8 million in the prior year. This improvement can be attributed to a $10.1 million reduction in net loss and positive cash impacts of $4.1 million from inventory management, $3.0 million from lower prepaid expenses and other assets, $1.5 million from reduced trade receivables, $1.6 million from higher accrued expenses and $0.9 million from higher provisions for doubtful trade receivables.

2023 Full Year Outlook

Looking forward, for the full year, the Company expects between 14% - 16% revenue growth year-over-year, driven by its global e-commerce business, steady growth from new and existing partn

EX-99.1

2 ex991-8kpressreleasexq22023.htm

EX-99.1

Document

ChromaDex Corporation Reports Second Quarter 2023 Financial Results

Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the three months ended June 30, 2023.

LOS ANGELES, CA - August 9, 2023 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2023.

Second Quarter 2023 and Recent Highlights

•Total net sales were $20.3 million, with $16.9 million from Tru Niagen®, up 21% and 16% from the prior year quarter, respectively.

•Strong gross margin of 60.8% and a $1.8 million reduction in operating expenses.

•Sales and marketing expense as a percentage of net sales was 29.6%, an improvement of 1,830 basis points, compared to 47.9% from the prior year quarter.

•Net loss was $2.2 million or $(0.03) per share, an improvement of $4.2 million, or $0.06 per share, from the prior year quarter.

•Adjusted EBITDA, a non-GAAP measure, was a positive $0.2 million, a $4.9 million improvement from the prior year quarter.

•Two published abstracts, originally presented in April 2023, highlighted the significance of NAD+ in glaucoma patients and that supplementation with nicotinamide riboside, NR, shows promising effects.(1)

•ChromaDex External Research Program (CERP™) celebrated its 10th anniversary, signing more than 275 global research agreements with over 235 independent, expert investigators to uncover the full potential of NAD+ with Niagen®. This research has shown that the health benefits of Niagen® translate from preclinical models to human clinical studies for brain, heart and muscle health with remarkable consistency. Looking to the next 10 years, there is great anticipation for emerging benefits in sensory, infant, maternal and reproductive health to be translated from preclinical to human studies.

“This was another excellent quarter, delivering 21% year-over-year revenue growth, positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the second consecutive quarter,” said ChromaDex Chief Executive Officer, Rob Fried. “We are again raising our 2023 revenue outlook by 2.5% to at least 15% growth, underscoring our commitment to consistent profitable growth.”

(1) Refers to two independent clinical study abstracts originally presented in April 2023 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting and recently published in the peer-reviewed ARVO journal, Investigative Ophthalmology & Visual Science.

Results of operations for the three months ended June 30, 2023 compared to the prior year quarter

ChromaDex reported a net sales increase of 21%, or $3.6 million, to $20.3 million. The increase in net sales was fueled by growth in sales of Tru Niagen® and growth in Niagen® ingredient sales.

Gross margin percentage improved 80 basis points to 60.8%. The improvement in gross margin percentage is primarily driven by economies of scale and supply chain management optimization efforts, partly offset by changes in business mix.

Operating expense decreased 11%, or $1.8 million, to $14.7 million driven by a $2.0 million reduction in sales and marketing expense slightly offset by higher research and development expense and general and administrative expense.

Net loss was $2.2 million, or $0.03 loss per share, compared to a net loss of $6.4 million or $0.09 loss per share for the second quarter of 2022. Adjusted EBITDA, a non-GAAP measure, was a positive $0.2 million, a $4.9 million improvement from Q2 2022. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of non-GAAP Adjusted EBITDA to net loss, the most directly comparable GAAP measure.

Net cash inflow from operating activities was $6.1 million for the six months ended June 30, 2023, showing a significant improvement compared to a net cash outflow of $11.0 million in the prior year. This improvement can be attributed to a $10.0 million reduction in net loss, a positive impact of $4.9 million from inventory management, as well as other favorable changes in working capital.

2023 Full Year Outlook

Looking forward, for the full year, the Company expects at least 15.0% revenue growth year-over-year. The projected growth considers only recurring, steady revenue growth from the e-commerce business and established partnerships, as well as upside from newer partnerships realized in the first half of the year. However, potential upside which is not reflected in this growth, lies within new partnerships, channels, and products. The Company projects that gross margin will remain stable year over year as cost savings initiatives and benefits from economies of scale are expected to largely offset continued inflationary pressures. Moreover, further optimization, coupled with new and focused customer acquisition strategies are expected to result in reduced

EX-99.1

2 ex991-8kpressreleasexq12023.htm

EX-99.1

Document

ChromaDex Corporation Reports First Quarter 2023 Financial Results

Record net sales of $22.6 million, with a strong gross margin of 59.9%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.9 million and $0.1 million, respectively, for the three months ended March 31, 2023.

LOS ANGELES, CA - May 10, 2023 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2023.

First Quarter 2023 and Recent Highlights

•Total net sales were $22.6 million, up 31% from the prior year quarter, with $17.6 million from Tru Niagen®.

•Strong gross margin of 59.9% and a $2.8 million reduction in operating expenses, reflecting financial discipline.

•Selling and marketing expense as a percentage of net sales was 34.9% versus 47.7%, an improvement of 1,280 basis points from the prior year quarter, while investing in a strategic brand building event.

•General and administrative expense decreased $2.5 million from the prior year quarter.

•Net loss was $1.9 million or $(0.03) per share, an improvement of $0.08 per share from the prior year quarter.

•Adjusted EBITDA, a non-GAAP measure, was a loss of only $0.1 million, a $4.4 million improvement from the prior year quarter.

“In the first quarter of fiscal 2023, we achieved $22.6 million in revenue and generated $2.8 million in positive operating cash flows,” said ChromaDex Chief Executive Officer, Rob Fried. “We raised the conservative end of our 2023 revenue outlook to 12.5% growth and, importantly, are seeing significant opportunities for future growth that are not reflected in this outlook."

Results of operations for the three months ended March 31, 2023 compared to the prior year quarter

ChromaDex reported a net sales increase of 31%, or $5.3 million, to $22.6 million. The increase in net sales was largely driven by growth in sales of Tru Niagen® and growth in Niagen® ingredient sales.

Gross margin percentage declined 110 basis points to 59.9%. The decline in gross margin percentage is largely attributable to a shift in business mix as well as modest cost inflation, partially offset by overall scale.

Operating expense decreased 15%, or $2.8 million, to $15.5 million driven by a $2.5 million reduction in general and administrative expense due to lower legal fees, share-based compensation and severance and restructuring costs.

Net loss was $1.9 million, or $0.03 loss per share, compared to a net loss of $7.7 million or $0.11 loss per share for the first quarter of 2022. Adjusted EBITDA, a non-GAAP measure, approached break-even with a loss of only $0.1 million, a $4.4 million improvement from Q1 2022. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of non-GAAP Adjusted EBITDA to net loss, the most directly comparable GAAP measure.

Net cash inflow from operating activities was $2.8 million compared to a cash outflow of $7.2 million in the prior year quarter, largely due to improvements in net loss of $5.8 million paired with changes in working capital.

2023 Full Year Outlook

Looking forward, for the full year, the Company expects at least 12.5% revenue growth year-over-year. The conservative end of the Company’s outlook reflects prevailing macroeconomic uncertainty and only considers recurring, steady revenue growth from the e-commerce business and established partnerships, as well as upside from new partnerships realized in the first quarter. However, potential upside lies within new partnerships, channels, and products. The Company projects that gross margin will remain stable year over year as cost savings initiatives are expected to largely offset continued inflationary pressures. Moreover, further optimization, coupled with new and focused customer acquisition strategies are expected to result in reduced selling and marketing expense as a percentage of net sales. The Company plans to increase investments in research and development to drive innovation and expects a reduction in general and administrative expense of $1 to $2 million year over year.

Investor Conference Call

A live webcast will be held Wednesday, May 10, 2023 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss ChromaDex’s first-quarter financial results and provide a general business update.

To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investors Relations section of ChromaDex’s website at http://chromadex.com. The toll-free dial-in information for this call is 1-888-330-2446 with Conference ID: 4126168.

The webcast will be recorded, and will be available for replay via the website from 7:30 p.m. Eastern time on May 10, 2023 through 11:59 p.m. Eastern time on May 17, 2023. The replay of the call can also be accessed by dialing 800-770-2030, using the Replay ID: 4126168.

Important Note on Forward Looking Statements:

This release contains forward-looking statements

EX-99.1

2 exhibit991-pressreleasexq4.htm

EX-99.1

Document

EXHIBIT 99.1

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results

Record revenue in Q4 2022 with $21.0 million in total net sales, up 18% from the prior year quarter, a net loss of $1.4 million and an Adjusted EBITDA profit of $0.4 million. Full year total net sales of $72.0 million with $60.1 million from Tru Niagen.

LOS ANGELES, CA - March 8, 2023 - ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results.

Fourth Quarter 2022 and Recent Highlights

•Total net sales were $21.0 million, up 18% from $17.8 million for the prior year quarter.

•Tru Niagen® net sales were $16.1 million, up 14% from $14.1 million for the prior year quarter.

•Selling and marketing expense as a percentage of net sales was 29.5% versus 48.7% in the prior year quarter, an improvement of 1,920 basis points.

•Net loss was $1.4 million or $0.02 loss per share, an improvement of $0.06 per share from the prior year quarter.

•Adjusted EBITDA, a non-GAAP measure, was a profit of $0.4 million, a $3.8 million improvement from the prior year quarter.

•Signed long-term supply agreement with Nestlé Health Science, extending non-exclusive rights to sell Niagen® in multi-ingredient dietary supplements.

•Raised $7.7 million, net of offering costs, with Nestlé Health Science and existing strategic investors in October 2022.

•Granted two new U.S. patents, including one on NRH, which preclinical research suggests may be among the most potent and efficient of the NAD+ precursors, and shows promise as a new therapeutic approach to ameliorating age-related NAD+ decline.

•Appointed Dr. Vilhelm Bohr, a leading aging and neurodegenerative disease researcher, to the Scientific Advisory Board.

•In December 2022, a clinical study published in the peer-reviewed journal Aging Cell finds that NR oral supplementation significantly increased NAD+ levels in the brain and positively impacted neurodegenerative biomarkers.

•In January 2023, a clinical study published in the peer-reviewed journal Science Advances finds that NR oral supplementation increased muscle mitochondrial biogenesis.

Full Year 2022 Highlights

•Delivered on latest financial outlook to investors across all metrics, and exceeded G&A outlook.

•Total net sales of $72.0 million, up 7% from $67.4 million year over year.

•Tru Niagen® net sales of $60.1 million, up 6% from $56.7 million year over year.

•Selling and marketing expense as a percentage of net sales improved 270 basis points year over year.

•General and administrative expense decreased $8.1 million year over year.

•Net loss was $16.5 million or $0.24 loss per share, an improvement of $0.16 per share year over year.

•Adjusted EBITDA, a non-GAAP measure, was a loss of $10.0 million, an $8.9 million improvement year over year.

•Granted additional U.S. continuation patent to protect the novel manufacturing process of NR and its various salt forms, which now cover NR Chloride, NR Malate, and NR Tartrate salts through 2037. ChromaDex also holds two patents covering crystal forms of important intermediates in the production of NR Chloride, one of which was granted in 2022.

•Signed agreement with Sinopharm Xingsha, a subsidiary of one of China’s largest pharmaceutical companies, to conduct cross-border sales of Tru Niagen® in Mainland China. Sinopharm Xingsha debuted Tru Niagen® at the China International Natural Health & Nutrition Expo (NHNE), a major trade show.

“ChromaDex proudly reported its best quarter ever, achieving $21.0 million in revenue in the fourth quarter, up 18% year-over-year and 23% sequentially,” said Rob Fried, ChromaDex Chief Executive Officer. “We also achieved $0.4 million in Adjusted EBITDA, an important operational milestone as we reposition ChromaDex for growth with profitability in mind during these turbulent economic times. We end the year with $20.4 million in cash, no debt, some excellent new partners with Nestlé and Sinopharm and are poised for a great 2023.”

Results of operations for the three months ended December 31, 2022

For the three months ended December 31, 2022 (“Q4 2022”), ChromaDex reported net sales of $21.0 million, an increase of $3.2 million, or 18%, compared to the fourth quarter of 2021 (“Q4 2021”). The increase in Q4 2022 revenues compared to Q4 2021 was driven by a $2.0 million increase in Tru Niagen® sales and $1.3 million higher Niagen® ingredient sales. Growth in Tru Niagen® sales was driven by higher sales to A.S. Watson, a related party, and a new partnership. Growth in Niagen® ingredient sales was due to an upfront minimum purchase commitment from Nestlé Health Science as part of the newly amended supply agreement.

Gross margin percentage declined by 400 basis points to 57.2% in Q4 2022 compared to 61.2% in Q4 2021. The decline in gross margin percentage is largely attributable to business mix and overall input cost and wage inflation.

Operating e

EX-99.1

2 ex991-8kpressreleasexq32022.htm

EX-99.1

Document

ChromaDex Corporation Reports Third Quarter 2022 Financial Results

Total net sales of $17.1 million, with gross margin of 59.8%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.0 million and $1.2 million, respectively, for the three months ended September 30, 2022.

LOS ANGELES, CA - November 2, 2022 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2022.

Third Quarter 2022 and Recent Highlights

•Total net sales were $17.1 million, with $14.6 million from Tru Niagen®, down (1)% each from the prior year quarter.

•Strong gross margin of 59.8% in the face of inflationary pressures in global supply chains.

•Selling and marketing expense as a percentage of net sales improved 730 basis points from the prior year quarter.

•General and administrative expense decreased $5.0 million from the prior year quarter driven by lower legal expense.

•Net loss was $1.0 million or $(0.01) per share, an improvement of $0.12 per share from the prior year quarter.

•Net loss, excluding the one-time Employee Retention Tax Credit recognition of $2.1 million ($0.03 per share), was $3.1 million, or $(0.04) per share, an improvement of $0.09 per share from the prior year quarter.

•Adjusted EBITDA including total legal expense, a non-GAAP measure, was a loss of $1.2 million, a $5.1 million improvement from the prior year quarter and approaching break-even.

•Clinical study published in October 2022 in the JACC(1) finds Niagen® safe and well-tolerated in patients with heart failure, marking a milestone for future clinical research. The study further found that Niagen® almost doubled whole blood NAD+ levels, increasing white blood cell mitochondrial respiratory function and decreasing the expression of inflammatory markers.

•Signed JV to pursue Blue Hat approval for Tru Niagen® in Mainland China, and Sinopharm Xingsha debuted Tru Niagen® at China International Natural Health & Nutrition Expo (NHNE), a major trade show.

•Signed long-term supply agreement with Nestlé Health Science, extending non-exclusive rights to sell Niagen® in multi-ingredient dietary supplements. Includes initial purchase commitment of approximately $2.0 million in 2022.

•In October, raised $7.7 million, net of offering costs, with Nestlé Health Science and existing strategic investors.

“We approached cash flow break even in the third quarter and remain on track to achieve this important objective next quarter,” said ChromaDex CEO, Rob Fried. “We finalized key strategic partnerships in China and signed a long-term supply agreement with Nestlé Health Science. Our position as the world's leading NAD+ company is solid, supported by our strong and growing patent portfolio, our globally trusted consumer brand, Tru Niagen®, and our pipeline of future innovations.”

(1) Journal of the American College of Cardiology: Basic to Translational Science

Results of operations for the three months ended September 30, 2022 compared to the prior year quarter

For the three months ended September 30, 2022 (“Q3 2022”), ChromaDex reported net sales of $17.1 million, a decrease of $0.2 million or (1)% compared to the third quarter of 2021 (“Q3 2021”). The slight decline in Q3 2022 revenues compared to Q3 2021 was primarily attributable to lower business-to-business sales of Tru Niagen® as distributor partners continue to experience COVID-19 headwinds and other macroeconomic factors paired with lower demand for research and development services. Declines in net sales were partially offset by steady growth in e-commerce sales of Tru Niagen®.

Gross margin percentage declined to 59.8% in Q3 2022 compared to 61.1% in Q3 2021 primarily due to increases in supply chain headcount, including higher wages, and other inflationary pressures, partially offset by business mix.

Operating expense decreased $6.1 million to $13.3 million in Q3 2022, compared to $19.4 million in Q3 2021. The decline in operating expense was largely attributable to a $5.0 million decrease in general and administrative expense paired with a $1.4 million decrease in selling and marketing expense. During Q3 2022, selling and marketing expense was scaled back to focus on the most efficient channels and investments, which drove a 730 basis point improvement in selling and marketing expense as a percentage of net sales, compared to Q3 2021. The decline in general and administrative expense was primarily driven by a $4.4 million decrease in legal expense.

The net loss for Q3 2022 was $1.0 million or $(0.01) per share compared to a net loss of $8.8 million or $(0.13) per share for Q3 2021. Adjusted EBITDA including legal expense, a non-GAAP measure, was a loss of $1.2 million for Q3 2022, a $5.1 million improvement from Q3 2021. Adjusted EBITDA excluding legal expense, a non-GAAP measure, was a profit of $0.1 million for Q3 2022. See “Reconciliation of Non-GAAP Financial Measures” for a

EX-99.1

2 exhibit991-pressreleasexq1.htm

EX-99.1

Document

ChromaDex Corporation Reports First Quarter 2022 Financial Results

Total net sales of $17.3 million for the three months ended March 31, 2022, up 18% from the prior year, with $14.9 million from Tru Niagen® and gross margin of 61.0% for the quarter.

LOS ANGELES, CA - May 12, 2022 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2022.

First Quarter 2022 and Recent Highlights

•Total net sales were $17.3 million, up 18% from the prior year quarter.

•Tru Niagen® net sales were $14.9 million, a 20% increase from the prior year quarter.

•In April 2022, the ChromaDex External Research Program (CERP) achieved its 250th material transfer agreement since 2013, resulting in over 100 peer-reviewed preclinical and clinical studies, many including the study of Niagen® and its impact on healthy aging.

•Clinical study published in Cell Metabolism revealed NR as a potential neuroprotective therapy for Parkinson’s Disease (PD) patients, warranting further investigation in additional trials. Two additional studies are underway, including a 400 patient study at 1,000 milligrams per day, and a 20 patient study at 3,000 milligrams per day.

•Launched new consumer product, Tru Niagen® Immune, a first-of-its kind combination of immune-boosting nutrition with ChromaDex’s proprietary NAD+ boosting ingredient Niagen®, beginning April 2022.

•Granted additional U.S. continuation patent to protect the novel manufacturing process of NR and its various salt forms, which now cover NR Chloride, NR Malate, and NR Tartrate salts, through 2037.

“We delivered solid financial results in the first quarter, while strengthening our patent portfolio, and announcing dramatic new scientific research on Niagen(R),” said CEO, Rob Fried. “Following the quarter, we launched Tru Niagen(R) Immune and ramped up our new TV campaign to encouraging early results.”

Results of operations for the three months ended March 31, 2022 compared to the prior year quarter

For the three months ended March 31, 2022 (“Q1 2022”), ChromaDex reported net sales of $17.3 million, up $2.6 million or 18% compared to the first quarter of 2021 (“Q1 2021”). The increase in Q1 2022 revenues was largely driven by growth in sales of Tru Niagen® (primarily e-commerce) paired with slight growth in ingredient sales.

Gross margin percentage declined to 61.0% in Q1 2022 compared to 62.9% in Q1 2021 primarily due to business mix and increases in supply chain headcount to scale the business.

Operating expenses increased by $1.7 million to $18.3 million in Q1 2022, compared to $16.6 million in Q1 2021. The increase in operating expenses was driven by $2.0 million of higher selling and marketing expenses partially offset by a $0.6 million decrease in general and administrative expense. The increase in selling and marketing expenses are largely due to brand building activities, including new Tru Niagen® television campaign.

The net loss for Q1 2022 was $7.7 million or $(0.11) per share compared to a net loss of $7.4 million or $(0.12) per share for Q1 2021. Adjusted EBITDA including legal expense, a non-GAAP measure, delivered a loss of $4.5 million for Q1 2022, a $1.2 million improvement from Q1 2021. Adjusted EBITDA excluding legal expense, a non-GAAP measure, was a loss of $2.1 million for Q1 2022. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of non-GAAP Adjusted EBITDA excluding legal expense to net loss, the most directly comparable GAAP measure.

For Q1 2022, the net cash outflow from operating activities was $7.2 million, compared to $5.4 million in Q1 2021 largely due to changes in working capital.

2022 Full Year Outlook

Looking forward, for the full year, the Company expects 15-20% revenue growth, driven by its global e-commerce business, as well as growth with existing and new strategic partners. The outlook does not include revenue upside from potential new partnerships in the pipeline. The outlook contemplates continued COVID-19 headwinds for international partners. The Company expects slightly better than 60% gross margin and a reduction in general and administrative expense of $5.0 to $6.0 million, as reported, for full year 2022, driven by lower legal expense. The Company expects to increase investments and resources to drive brand awareness and accelerate its research and development pipeline to capitalize on growth in the nicotinamide adenine dinucleotide (NAD+) market globally. Accordingly, the Company expects an increase in research and development expense of approximately $2.0 million. Selling and marketing expense is expected to be up in absolute dollars, but down slightly as a percentage of net sales, year-over-year.

Investor Conference Call

A live webcast will be held Thursday, May 12, 2022 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss ChromaDex’s first-quarter financial results and provide a general business

EX-99.1

2 exhibit991-pressreleasexq4.htm

EX-99.1

Document

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results

Total net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen® and gross margin of 61.5%. Total net sales of $17.8 million for the three months ended December 31, 2021, up 15% from the prior year quarter.

LOS ANGELES, CA - March 9, 2022 - ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2021 financial results.

Fourth Quarter 2021 and Recent Highlights

•Total net sales were $17.8 million, up 15% year over year.

•Tru Niagen® net sales were $14.1 million, a 14% increase year over year.

•Gross margin was 61.2%, up 20 basis points year over year.

•Net loss was $5.3 million or $0.08 loss per share, an improvement of $0.02 per share year over year.

•In January 2022, announced a supply agreement with Designs for Health to sell Niagen® in specially-formulated products, available exclusively through the company’s extensive healthcare practitioner network.

•The ChromaDex External Research Program (CERP) celebrates 100 published peer-reviewed studies on Niagen® and other ingredients. This research conducted by independent investigators has expanded the understanding of nicotinamide riboside (NR) in key health areas including Ataxia-telangiectasia, skeletal muscle, liver health, and heart failure.

•Clinical study published in Cell Metabolism finds that NR supplementation significantly increased cerebral NAD levels, and decreased levels of inflammatory cytokines in Parkinson’s Disease (PD) patients, building on positive preclinical research supporting NR’s positive impact on neurodegenerative diseases. Further studies are underway to understand the role of NR supplementation in Parkinson’s patients.

•New U.S. continuation patent reinforces ChromaDex’s intellectual property portfolio of over 40 patents on NR and other NAD precursors by adding protection of a novel manufacturing process of NR and its various salt forms.

Full Year 2021 Highlights

•Delivered on latest financial outlook to investors across all metrics. Slightly better than target on research and development, general and administrative expense.

•Total net sales of $67.4 million, up 14% from $59.3 million year over year.

•Tru Niagen® net sales of $56.7 million, a 20% increase from $47.1 million year over year.

•Gross margins of 61.5%, a 200 basis point increase year over year.

•Announced strategic supply agreements with Health & Happiness Group (H&H), a global leader in premium health, human and pet nutrition and personal care brands, and healthcare technology company, Ro, to sell Niagen® in exclusively formulated Swisse™ and Roman products, respectively. Roman Life launched in September 2021.

•Launched Tru Niagen® in 3,800 Walmart stores across the United States in June.

•Announced partnership with Sinopharm Xingsha, a subsidiary of one of China’s largest pharmaceutical companies, to conduct cross-border sales of Tru Niagen in mainland China, and collaborate to secure health food registration.

“ChromaDex achieved solid net sales growth in 2021 and recent scientific developments continue to validate the market opportunity for Tru Niagen®,” said Rob Fried, ChromaDex Chief Executive Officer. “In 2022, we expect to introduce a new Tru Niagen® product, strengthen our presence in the Asia-Pacific region, and continue to grow the industry-leading ChromaDex External Research Program.”

Results of operations for the three months ended December 31, 2021 compared to the prior year quarter

Net Sales for ChromaDex increased 15%, or $2.3 million, to $17.8 million. The increase in net sales was largely driven by growth in sales of Tru Niagen® (primarily e-commerce sales) paired with growth in Niagen® and other ingredient sales.

Gross Margin improved 20 basis points to 61.2% primarily driven by the positive impact of increased Tru Niagen® consumer product sales and product cost savings initiatives.

Operating Expense increased 4%, or $0.7 million, to $16.2 million.

•Selling and marketing (S&M) expense increased 37%, or $2.3 million, largely due to brand building activities and efforts to increase consumer awareness and demand.

•Increases were partially offset by a 22% decrease, or $1.8 million decline, in general and administrative (G&A) expense primarily related to lower legal expense.

Net Loss was $5.3 million, or $0.08 loss per share, compared to a net loss of $6.1 million or $0.10 loss per share for the fourth quarter of 2020.

Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of $1.8 million, an increase of $0.7 million from a loss of $1.1 million for the fourth quarter of 2020. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of non-GAAP Adjusted EBITDA excluding total legal expense to net loss, the most directly comparable GAAP measure.

Operating Activities had a net cash outflo

EX-99.1

2 exhibit991-pressreleasexq3.htm

EX-99.1

Document

ChromaDex Corporation Reports Third Quarter 2021 Financial Results

Total company net sales of $17.3 million for the three months ended September 30, 2021, with Tru Niagen® net sales of $14.8 million, up 24% from the prior year quarter and gross margin of 61.1% for the quarter.

LOS ANGELES, CA - November 3, 2021 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2021.

Third Quarter 2021 and Recent Highlights

•Total net sales were $17.3 million, up 22% from the prior year quarter.

•Tru Niagen® net sales were $14.8 million, a 24% increase from the prior year quarter.

•Gross margin was 61.1%, a 150 basis point increase from the prior year quarter.

•Net loss was $(8.9) million or $(0.13) per share, a decline of $0.06 per share from the prior year quarter.

•Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of $(0.6) million, a $0.5 million decline from the prior year quarter.

•Announced partnership with Sinopharm Xingsha, a subsidiary of one of China’s largest pharmaceutical companies, to conduct cross-border sales of Tru Niagen in Mainland China, and collaborate to secure Health Food Registration.

•Study published in September 2021 on nicotinamide riboside (NR) supplementation in children with Ataxia-Telangiectasia (AT), a prematurely aging population, showed improvement in ataxia scores and increased antibodies in immune-compromised patients.

•Clinical study published in October 2021 in Molecular Systems Biology finds nutritional protocol including nicotinamide riboside (NR) significantly decreases liver fat and improves liver function.

“This quarter marks an inflection point for ChromaDex,” said CEO, Rob Fried. “With the litigation largely behind us, we are focusing more resources, both human and financial, on building the Tru Niagen® brand, furthering our science, and developing our global partnerships. We recently partnered with Sinopharm Xingsha, one of the most prestigious healthcare companies in China, which will enable us to capitalize on the tremendous opportunity for Tru Niagen® in that market.”

Results of operations for the three months ended September 30, 2021

For the three months ended September 30, 2021 (“Q3 2021”), ChromaDex reported net sales of $17.3 million, up $3.1 million or 22% compared to the third quarter of 2020 (“Q3 2020”). The increase in Q3 2021 revenues was largely driven by growth in sales of Tru Niagen® paired with slight growth in Niagen® and other ingredient sales.

Gross margin percentage improved by 150 basis points to 61.1% in Q3 2021 compared to 59.6% in Q3 2020. The improvement in gross margin percentage was driven by the positive impact of increased Tru Niagen® consumer product sales and product cost savings initiatives.

Operating expenses increased by $6.8 million to $19.4 million in Q3 2021, compared to $12.7 million in Q3 2020. The increase in operating expenses was driven by $2.0 million of higher selling and marketing expenses and a $4.6 million increase in general and administrative expense. The increase in general and administrative expense was primarily driven by $3.7 million of higher legal expense.

The net loss for Q3 2021 was $(8.9) million or $(0.13) per share as reported compared to a net loss of $(4.2) million or $(0.07) per share for Q3 2020 as reported. Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of $(0.6) million for Q3 2021, compared to a loss of $(0.1) million for Q3 2020, a $0.5 million decline. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of non-GAAP Adjusted EBITDA excluding total legal expense to net loss, the most directly comparable GAAP measure.

For Q3 2021, the net cash outflow from operating activities was $(5.9) million, compared to $(3.8) million in Q3 2020.

2021 Full Year Outlook

Looking forward, for the full year, the Company expects continued, steady revenue growth driven by its global e-commerce business, as well as growth with existing and new strategic partners. The Company expects slightly better than 60% gross margin and slightly higher general and administrative expense, excluding severance, restructuring and legal expense, for full year 2021. The Company plans to increase investments and resources to drive brand awareness and accelerate its research and development pipeline to capitalize on growth in the nicotinamide adenine dinucleotide (NAD+) market globally. Accordingly, the Company expects higher research and development expense and higher selling and marketing expense as a percentage of net sales year-over-year.

Investor Conference Call

A live webcast will be held Wednesday, November 3, 2021 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss ChromaDex’s third-quarter financial results and provide a general business update.

To listen to the webcast, or to view the earnings press release and its accompanying fi